GlobeNewswire by notified

Turning the Tables on Non-Productive Screen Time: Game On, Kids!

Share

LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- A new app, GenMove, released by app developer G13R Ltd, in collaboration with the World Health Organization, combines artificial intelligence (AI) and the selfie camera to create a fun and playful gamified exercise experience. GenMove aims to get more children up off the couch and moving and, in doing so, turn the tables on the sedentary lifestyle that is largely driven by more and more screen time.

Any parent knows that sinking feeling when they try to pry their children away from their phones, tablets, and computer screens. It's like preparing for battle. The addictive tendencies and impacts of too much screen time are undeniable.

The GenMove app literally puts its players in the game - through AI body tracking - and provides a high-intensity exercise experience, encouraging its players to coordinate their body movement to control their progress through a series of games and levels. 

The GenMove app allows its players to self-regulate the intensity of the experience, making it playable by children of all shapes and sizes. The games themselves only require a small floor footprint, making it playable anywhere, even in the living room on a cold and wet winter's day.

Already in its first week of the app's launch, the developers of GenMove (G13R Ltd), are seeing player session times clocking up over an hour of movement, with many of its players now spending several hours per week in the app, highlighting the potential of this new form of physical play.

GenMove is a useful tool in the effort by parents to limit nonproductive screen time for their children. Not only is increasing screen time contributing to a sedentary lifestyle - which along with poor diet is, in turn, correlated with obesity - but we now also know that lack of physical activity can exacerbate mental health issues. 

"We like to think of GenMove as gaming for good, in which children choose to play GenMove over typical sedentary computer games," says Andrew Hall, CEO of GenMove. "We achieve this by leveraging all of the recent advancements in gamification to motivate our players to want to move more. We engage children in movement, where and how they want to play. Parents should be ready for children to ask to play GenMove again and again."

Fiona Bull, head of the physical activity unit at the World Health Organization, says, "We now estimate that over 80 percent of children do not meet the physical activity guidelines of an average of 60 minutes every day. We are delighted to collaborate to bring GenMove Season 1 to the global community for free use, and to promote new forms of physical activity to a new generation, including those with mobility limitations, as there are games available for people who use wheelchairs."

GenMove, is a new take on screen time to get more children more active. GenMove, Season 1, in collaboration with the World Health Organization, is now available to download and play free of charge on iOS and Android. GenMove supports iOS 14 and above (which includes 98 percent of all Apple mobile devices operational today) and Android 10 and above (80 percent of all Android mobile devices operational today). GenMove is optimized for tablets, but can also be played on a smaller device such as a smartphone, or paired with a smart TV for a bigger and better screen experience.

Free GenMove App Download: https://onelink.to/genmove

Media Pack:link

Website:www.getgenmove.com

Contact Information:
Fiona Bull
Head of Physical Activity Unity WHO
bullf@who.int

Andrew Hall
CEO G13R Ltd
andrew@g13r.com

Related Files

GenMove_PressRelease_Jump.gif

GenMove_PressRelease_BubblePop.gif

Related Images



To view this piece of content from cdn.newswire.com, please give your consent at the top of this page.


Image 1: GenMove Logo



This content was issued through the press release distribution service at Newswire.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Graid Technology Announces Software Update Targeted at Enhancing Business Continuity for NVMe Deployments2.2.2023 15:00:00 CET | Press release

SupremeRAID™ new high availability feature provides an additional level of business continuity protection coupled with superior overall performance. SANTA CLARA, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Graid Technology, the award-winning data protection provider and developer of the only RAID card to offer customers access to the full performance of NVMe SSDs, is proud to announce its latest software release (V1.3) for SupremeRAID™ SR-1000 and SR-1010. The various enhancements in this release include features and software updates designed to support dual controller high availability along with support for multiple new NVMe SSDs. Among the enhanced features in the new release is a configurable strip size, allowing customers using RAID 0 and RAID 10 to realize even better server performance, a strategic move that continues to position SupremeRAID™ as the performance leader for both random and sequential workloads. "This latest release gives our customers peace of mind knowing that thei

Global Chauffeur Service Blacklane names Cindy Rubbens as Chief People Experience Officer and Gudrun Herrmann as Global Head of Communications2.2.2023 14:45:44 CET | Press release

Rubbens will oversee the continuous scaling of Blacklane while driving growth via learning and development, while Herrmann is tasked with building up an external and internal strategic communications function and co-drive its sustainability efforts. BERLIN, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Global chauffeur service, Blacklane, announced that it has named Cindy Rubbens Chief People Experience Officer (CPXO) and Gudrun Herrmann Global Head of Communications, effective immediately. Both will report to Blacklane CEO and CO-Founder Dr. Jens Wohltorf and will be charged with developing the Talent Attraction and Human Resources as well as Communications respectively during the company’s bid to scale while driving the next phase of growth. In her role as CPXO, Rubbens will support the sustainable development of Blacklane’s crew while the business continues scaling new, industry-leading services and expanding markets. Rubbens will focus on strengthening the Talent Attraction function while assi

Landsbankinn hf.: Financial results of Landsbankinn for 20222.2.2023 14:36:13 CET | Press release

Landsbankinn's net profit in 2022 was ISK 17.0 billion. There was good growth in loans to corporates, ISK 92.0 billion or the equivalent of 10%, having regard for currency changes.Mortgage loans grew by 59.0 billion with demand decreasing in the fourth quarter.ROE in the fourth quarter of 2022 was 8.2%, compared with 10.5% ROE in the same quarter of 2021. ROE in 2022 was 6.3%, despite solid core earnings. The negative impact reducing profitability was mainly a decrease in the fair value of the Bank’s holding in Eyrir Invest hf. The Bank’s target ROE is 10% at a minimum. Operating expenses are stable. Landsbankinn topped the Icelandic Performance Satisfaction Index for banking customers the fourth year in a row. The Bank’s market share in the retail market has never been higher and measures over 40% for the first time. Loans in arrears are at a historic low and loans in arrears were 0.2% at the turn of the year.In 2022, the Bank paid a dividend of ISK 20.5 billion and ISK 14.1 billion i

Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference2.2.2023 14:00:00 CET | Press release

BOSTON and LONDON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced that members of its management team will participate in a fireside chat at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 8:00 a.m. ET. A webcast of the fireside chat, as well as an archived recording, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations. About Centessa Pharmaceuticals Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications. We operate with the conviction that

MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa2.2.2023 14:00:00 CET | Press release

MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody®sonelokimab in moderate-to-severe hidradenitis suppurativa Enrollment target of 210 patients randomized completed ahead of scheduleTop line results on the primary endpoint, for the novel IL-17A and IL-17F inhibitor Nanobody® sonelokimab, expected mid-2023First registered randomized trial in HS to use HiSCR75 as the primary endpoint; trial also includes adalimumab as an active reference armThe trial will proceed to its 24-week completion, including placebo patients re-randomized to sonelokimab and adalimumab patients switched to sonelokimab, with final read out expected, as planned, by Q4 2023 ZUG, Switzerland, February 2, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has completed enrollment of the target 210 pa